000307319 001__ 307319
000307319 005__ 20260213120749.0
000307319 0247_ $$2doi$$a10.1007/s00262-025-04238-2
000307319 0247_ $$2pmid$$apmid:41410751
000307319 0247_ $$2ISSN$$a0340-7004
000307319 0247_ $$2ISSN$$a1432-0851
000307319 037__ $$aDKFZ-2025-03005
000307319 041__ $$aEnglish
000307319 082__ $$a610
000307319 1001_ $$aPavlov, Sergii$$b0
000307319 245__ $$aSpatial patterns and prognostic relevance of CD1a+ immature and CD208+ mature dendritic cells in colorectal cancer from non-tumor adjacent mucosa to liver metastases.
000307319 260__ $$aHeidelberg$$bSpringer$$c2026
000307319 3367_ $$2DRIVER$$aarticle
000307319 3367_ $$2DataCite$$aOutput Types/Journal article
000307319 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767090797_1386404
000307319 3367_ $$2BibTeX$$aARTICLE
000307319 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000307319 3367_ $$00$$2EndNote$$aJournal Article
000307319 520__ $$aThe prognostic role of dendritic cells (DCs) in colorectal cancer (CRC) and paired liver metastases (LM) remains unclear, particularly regarding the dynamics of immature CD1a+ and mature CD208+ subsets across anatomical compartments and synchronous versus metachronous disease.This retrospective cohort included patients undergoing resection of primary CRC (pCRC) and synchronous LM (N = 55) or metachronous LM (N = 44). Immunohistochemical staining for CD1a and CD208 was performed on non-tumor adjacent mucosa (NAM), as well as tumor center (TC), inner margin (IM), outer margin (OM), and peritumoral zone (PT) of both pCRC and LM. Cell densities were quantified on whole-slide images using QuPath software and correlated with overall survival (OS).CD1a+ DCs were nearly absent in NAM but enriched in pCRC TC, whereas CD208+ DCs predominated in lymphoid aggregates associated with NAM and peripheral compartments of pCRC and LM. CD1a+ cells followed a TC/IM > OM/PT gradient, while CD208+ cells showed the opposite, consistent with a recruitment-maturation axis. In synchronous cases, CD1a+ densities were higher in pCRC than LM, supporting the role of the primary tumor as a 'monocyte reservoir.' Survival analysis revealed that high CD208+ density in TC of synchronous LM (hazard ratio (HR) = 0.47; p = 0.033) and high CD1a+ density in TC of metachronous LM (HR = 0.44; p = 0.050) were both associated with reduced mortality risk.This study provides the first detailed mapping of CD1a+ and CD208+ DCs across NAM, pCRC and paired LM, indicating that their prognostic impact is determined not only by absolute numbers but, more importantly, by compartmental distribution and the temporal pattern of metastasis.
000307319 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000307319 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000307319 650_7 $$2Other$$aImmature and mature dendritic cells
000307319 650_7 $$2Other$$aOverall survival
000307319 650_7 $$2Other$$aPrimary colorectal cancer
000307319 650_7 $$2Other$$aSpatial immune profiling
000307319 650_7 $$2Other$$aSynchronous and metachronous liver metastases
000307319 650_7 $$2NLM Chemicals$$aAntigens, CD1
000307319 650_7 $$2NLM Chemicals$$aCD1a antigen
000307319 650_7 $$2NLM Chemicals$$aLectins, C-Type
000307319 650_7 $$2NLM Chemicals$$aCLEC4C protein, human
000307319 650_7 $$2NLM Chemicals$$aAntigens, CD
000307319 650_7 $$2NLM Chemicals$$aMembrane Glycoproteins
000307319 650_7 $$2NLM Chemicals$$aReceptors, Immunologic
000307319 650_2 $$2MeSH$$aHumans
000307319 650_2 $$2MeSH$$aColorectal Neoplasms: pathology
000307319 650_2 $$2MeSH$$aColorectal Neoplasms: immunology
000307319 650_2 $$2MeSH$$aColorectal Neoplasms: mortality
000307319 650_2 $$2MeSH$$aColorectal Neoplasms: metabolism
000307319 650_2 $$2MeSH$$aDendritic Cells: immunology
000307319 650_2 $$2MeSH$$aDendritic Cells: metabolism
000307319 650_2 $$2MeSH$$aDendritic Cells: pathology
000307319 650_2 $$2MeSH$$aLiver Neoplasms: secondary
000307319 650_2 $$2MeSH$$aLiver Neoplasms: immunology
000307319 650_2 $$2MeSH$$aAntigens, CD1: metabolism
000307319 650_2 $$2MeSH$$aAntigens, CD1: immunology
000307319 650_2 $$2MeSH$$aPrognosis
000307319 650_2 $$2MeSH$$aMale
000307319 650_2 $$2MeSH$$aFemale
000307319 650_2 $$2MeSH$$aMiddle Aged
000307319 650_2 $$2MeSH$$aRetrospective Studies
000307319 650_2 $$2MeSH$$aAged
000307319 650_2 $$2MeSH$$aLectins, C-Type: metabolism
000307319 650_2 $$2MeSH$$aAdult
000307319 650_2 $$2MeSH$$aMucous Membrane: pathology
000307319 650_2 $$2MeSH$$aMucous Membrane: immunology
000307319 650_2 $$2MeSH$$aAged, 80 and over
000307319 650_2 $$2MeSH$$aAntigens, CD: metabolism
000307319 650_2 $$2MeSH$$aMembrane Glycoproteins
000307319 650_2 $$2MeSH$$aReceptors, Immunologic
000307319 7001_ $$aAli, Esraa$$b1
000307319 7001_ $$aYe, Wenjing$$b2
000307319 7001_ $$aČervenková, Lenka$$b3
000307319 7001_ $$aAmbrozkiewicz, Filip$$b4
000307319 7001_ $$aVyčítal, Ondřej$$b5
000307319 7001_ $$aDaum, Ondřej$$b6
000307319 7001_ $$aLiška, Václav$$b7
000307319 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b8$$udkfz
000307319 7001_ $$aTrailin, Andriy$$b9
000307319 773__ $$0PERI:(DE-600)1458489-X$$a10.1007/s00262-025-04238-2$$gVol. 75, no. 1, p. 4$$n1$$p4$$tCancer immunology immunotherapy$$v75$$x0340-7004$$y2026
000307319 8564_ $$uhttps://inrepo02.dkfz.de/record/307319/files/s00262-025-04238-2-3.pdf$$yOpenAccess
000307319 8564_ $$uhttps://inrepo02.dkfz.de/record/307319/files/s00262-025-04238-2-3.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000307319 909CO $$ooai:inrepo02.dkfz.de:307319$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000307319 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000307319 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000307319 9141_ $$y2025
000307319 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-06
000307319 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-06
000307319 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-06
000307319 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-06
000307319 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-06
000307319 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-06
000307319 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER IMMUNOL IMMUN : 2022$$d2024-12-06
000307319 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-06
000307319 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-06$$wger
000307319 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-06
000307319 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000307319 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-06
000307319 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER IMMUNOL IMMUN : 2022$$d2024-12-06
000307319 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-06
000307319 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-06
000307319 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000307319 9201_ $$0I:(DE-He78)Z999-20160331$$kZ999$$lErimitus im DKFZ$$x1
000307319 980__ $$ajournal
000307319 980__ $$aVDB
000307319 980__ $$aUNRESTRICTED
000307319 980__ $$aI:(DE-He78)C020-20160331
000307319 980__ $$aI:(DE-He78)Z999-20160331
000307319 9801_ $$aFullTexts